Publications by the researcher in collaboration with Luis Paz-Ares Rodríguez (14)

2023

  1. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 25, 5, (1252-1267), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology

  2. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267

  3. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112

  4. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  5. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

  6. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  2. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

  3. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2019

  1. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

    Nature Medicine, Vol. 25, Núm. 11, pp. 1783-1795

  2. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2017

  1. Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer

    Oncotarget, Vol. 8, Núm. 62, pp. 105196-105210

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2015

  1. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3